1 Factors associated with viral load suppression and indicators of stigma among people

2 living with HIV in Dar es Salaam tertiary hospitals, Tanzania

- 3 Mary Spicar Kilapilo¹, Idda Hubert Mosha², George Msema Bwire¹, Godfrey Leonard Sambayi³,
- 4 Raphael Zozimus Sangeda^{1*}, Japhet Killewo⁴
- 5
- 6 ¹Department of Pharmaceutical Microbiology, Muhimbili University of Health and Allied
- 7 Sciences, Dar es Salaam, Tanzania.
- 8 ²Department of Behavioural Sciences, Muhimbili University of Health and Allied Sciences, Dar
- 9 es Salaam, Tanzania.
- 10 ³Department of Pharmacognosy, Muhimbili University of Health and Allied Sciences, Dar es
- 11 Salaam, Tanzania.
- 12 ⁴Department of Biostatistics and Epidemiology, Muhimbili University of Health and Allied
- 13 Sciences, Dar es Salaam, Tanzania.
- 14 Correspondence author:
- 15 Email: <u>sangeda@gmail.com</u> (RZS)
- 16
- 17

18 Abstract

19 Perception of stigma can contribute to virological failure among people living with HIV (PLHIV). 20 This study was conducted to assess the effect of stigmatization and self-discrimination on viral 21 load suppression among PLHIV at tertiary hospitals in Dar es Salaam, Tanzania. This was a 22 hospital-based cross-sectional study conducted in Temeke Regional Referral Hospital (RRH) and 23 Amana RRH at the Care and Treatment Clinic (CTC) between July and August 2020 using a 24 structured questionnaire with open and close-ended questions. Factors for stigmatization and viral 25 load suppression were compared using the Chi-square test, while factors for viral load suppression 26 were analyzed using multinomial logistic regression analysis. Altogether, 406 PLHIV participated, 27 with most female respondents, 298 (73.2%). The majority (50%) were aged between 25 and 44 28 years, whereas 171 (42.5%) respondents were married. Most of the participants, 382 (94.6%), were 29 on a dolutegravir-based regimen, with the majority, 215 (52.8%), having a refilling interval of 30 three months. The majority of the respondents, 379 (93.1%), disclosed their status. Most 31 participants, 355 (87.4%), preferred having a separate HIV clinic, while 130 (32.1%) participants 32 were not ready to be attended by the health care workers (HCWs) familiar to them. Male patients 33 were 60% less likely to suppress their viral load as compared to female patients (adjusted odds 34 ratio [aOR]: 0.4, 95% confidence interval [95%]: 0.19 - 0.77, p = 0.007). Refill interval was 35 significantly associated with viral load suppression. For example, patients with a one-month refill 36 interval had odds of 0.01 (95% CI: 0.003-0.42, p < 0.0001) compared to six-month refill intervals. 37 Stigmatization elements appeared to influence the viral load suppression among PLHIV. Factors 38 such as gender and refill time interval were significantly associated with viral load suppression 39 among HIV patients in the Dar es Salaam region.

40 Keywords: Self-discrimination, Stigmatization, Dolutegravir, Dar es Salaam, HIV, viral
41 load suppression, people living with HIV, Tanzania

42 Introduction

Viral load suppression indicates disease progression, wellness, antiretroviral therapy (ART)
effectiveness and minimized HIV drug resistance (HIVDR). On the other hand, virological failure
indicates the inverse and is associated with HIVDR [1]. Upon characterization of the factors
contributing to non-adherence, stigmatization was found to have a major link with non-adherence
[2,3].

PLHIV continue to suffer from stigma and discrimination from their family and communities. Evidence from research suggests that HIV-related stigma and self-stigmatization result in a delay in the disclosure of HIV serostatus, which is a potential barrier to HIV counseling, retention in care and treatment, and uptake of and adherence to ART [4]. AIDS-related stigma and discrimination impede millions of PLHIV from accessing and benefiting from effective prevention and treatment services [5].

54 Self-stigmatization among PLHIV is one of the consequences of stigma from the community. The 55 perception may force PLHIV to hide their serostatus and, in many cases, to continue engaging in 56 high-risk behaviors [6]. Therefore, this study was conducted to assess the effect of stigmatization 57 and self-discrimination on viral load suppression among PLHIV attending care and treatment 58 clinics at Amana and Temeke RRHs in Dar es Salaam, Tanzania.

59 Materials and methods

60 Study design and area and period of the study

A hospital-based cross-sectional study was conducted in Temeke Regional Referral Hospital
(RRH) and Amana RRH at the Care and Treatment Clinic (CTC) in Dar es Salaam, Tanzania,
between July and August 2020. Dar es Salaam city was selected to represent the regions found in
Tanzanian Mainland. Dar es Salaam is the largest city, business and the former capital of Tanzania,
with an approximated population of more than five million people (almost 10% of the country's
population) [7].

67 Study population and sampling

A total of 406 PLHIV aged above 18 years and used antiretrovirals (ARVs) for more or equal to six months and attended Amana and Temeke RRHs participated in this study. The sample size was derived using the cross-sectional formula [8] and the assumed prevalence from the previous study [9]. A systematic approach was used during the recruitment of research participants. This was done by obtaining a sampling interval "n" (total patients on CTC divided by 200). Then a patient was sampled after every "n" interval.

74 Data collection tool

A structured questionnaire with open and close-ended questions was prepared following an intensive literature review on a topic related to stigmatization, adherence and viral load suppression [9–11]. The English questionnaire was designed and translated to Kiswahili (local language). The Kiswahili questionnaire was uploaded on REDCap (Research Electronic Data Capture). REDCap is an electronic data capture tool hosted at Muhimbili University of Health and Allied Sciences (MUHAS) [12,13]. The questionnaire was tested on a pilot population of 30

patients (15 from each CTC). The updated Kiswahili questionnaire was then used to collect patients' demographics, pharmacy refill, and ART adherence factors. Data was collected using tablets and coded in the REDcap after being translated into English. REDCap data were downloaded, cleaned in excel (to remove incomplete forms), then exported to Statistical Package for Social Sciences (SPSS software version 25, Chicago Inc., USA) for analysis.

86 Data management and analysis

87 Descriptive statistics were summarized using frequencies and percentages. Stigmatization was 88 estimated using the HIV stigma toolkit described elsewhere [14]. A Chi-square test was employed 89 to analyze the association between categorical variables such as gender, refill interval, regimen 90 used and HCWs preference and viral load suppression. Viral load suppression and high viral load 91 were defined as viral load counts below 1,000 copies/ml and above 1,000 copies/ml, respectively 92 [15]. Factors associated with viral load suppression were controlled using a binary regression 93 model. Factors with a p-value less than 0.2 in univariate regression were qualified for multivariate 94 logistic regression [16]. A p-value of less than 0.05 was considered statistically significant.

95 Ethical considerations

96 Ethical clearance **MUHAS** Institutional Board was sought from the Review 97 (DA.25/111/01/10/02/2021). Temeke RRH and Amana RRH permitted the study to be conducted 98 on their respective premises and patients. All participants provided written informed consent for 99 participation. The consent included information on the description of the study, data privacy/ 100 confidentially and handling. Patients who reported self-discrimination and stigmatization were 101 counseled on medication adherence. Preventive measures for the COVID-19 pandemic were 102 observed during the whole period of data collection.

103 **Results**

- 104 Overall, 406 PLHIV were included in this study, with 205 PLHIV from Amana RRH and 201
- 105 PLHIV from Temeke RRH. Most of the respondents were female, 298 (73.2%), and the majority
- 106 (50%) were between 25 and 44 years old. The majority of the respondents, 151 (38.2%), received
- 107 ART for 7 to 12 years. In addition, the majority of study respondents, 171 (42.5%), were married
- and most participants, 382 (94.6%), reported to be on a dolutegravir-based regimen. The majority,
- 109 215 (52.8%), had a refill interval of three months (Table 1).

110 Table 1. Participants' socio-demographic characteristics

Variable	Category	Frequency N (%)
Gender	Female	298 (73.2)
(n = 406)		
	Male	108 (26.5)
Age	18 - 24	33 (8.2)
(n = 404)		
	25 - 44	202 (50.0)
	45 - 54	108 (26.7)
	55 - 64	48 (11.9)
	≥ 65	13 (3.2)
Hospital facility	Amana RRH	205 (50.4)
(n = 406)		

	Temeke RRH	201 (49.4)
Start ARV use (years)	< 2	80 (20.3)
(n = 395)		
	3 - 6	103 (26.1)
	7 - 12	151 (38.2)
	≥ 12	61 (15.4)
Marital status	Married	171 (42.0)
(n = 402)		
	Single	106 (26.0)
	Divorced	79 (19.4)
	Widowed	46 (11.3)
On dolutegravir based regimen	Yes	382 (94.6)
(n = 404)		
	No	22 (5.4)
Refill interval (months)	1	83 (20.4)
(n = 406)	2	7 (1.7)
	3	215 (52.8)
	6	101 (24.8)
Cost for a single hospital visit	< 2000	283 (69.9)
(TZS)		
(n = 405)		
	≥ 2000	87 (21.4)
	No cost	35 (8.6)

Waiting time at CTC (hours)	< 0.5	51 (12.6)
(n = 405)	0.5 - 1	137 (33.8)
	1 – 2	128 (31.6)
	> 2	89 (22)
Traveling time from home to CTC	< 0.5	105 (25.9)
(hours)		
(n = 406)	0.5 - 1	188 (46.3)
	1 – 2	91 (22.4)
	> 2	22 (5.3)

Key: RRH: Regional Referral Hospital

112

113

114 Status disclosure among people living with HIV

115 The majority of the respondents, 378 (93.1%), disclosed their HIV status. The majority, 352 116 (93.6%) of those disclosing their HIV status, were consequently encouraged to take medication. 117 Most of the participants, 246 (61.2%), reported concealing their HIV status to themselves, while 118 212 (52.7%) reported not having a reminder person or tool to assist them in taking their medication 119 on time. When asked about the reminder person or a reminder tool, the majority of the participants, 120 52.7%, reported a lack of reminders. In contrast, the remaining participants, 24.4%, said their 121 partners remind them. In comparison, 19.7% are reminded by their family members, and 6.7% 122 reported using a phone and other devices to remind them to take medication (Table 2).

123 Table 2. Status disclosure among people living with HIV

Variable	Categories	Frequency	
		(%)	
Disclosure of HIV status	Yes	378 (93.1)	
(n = 406)	No	28 (6.9)	
Response after disclosing the status	They encouraged me to take	352 (93.6)	
	medication		
	They supported me Financially	111(29.5)	
	and Socially		
	They felt stigmatized me	15 (4.0)	
	They left me to deal with it	12 (3.2)	
	alone		
Preference to keep a secret their HIV	Prefer to keep a secret	246 (61.2)	
status	Do not prefer to keep a secret	156 (38.8)	
(n = 402)			
Who is the reminder person to assist	No one reminds me	212 (52.7)	
in taking medication	Yes, I am reminded by	168 (41.3)	
	someone.		
	Phone alarm Reminds me.	27 (6.0)	

- 125
- 126
- 127

128 Self-discrimination and stigmatization

- 129 Of all participants, 355 (87.4%) reported that they preferred having a separate HIV clinic for HIV
- 130 patients. When asked for a reason, most participants, 309 (87.0%), reported that a separate HIV
- 131 CTC is a free space for HIV patients. Most participants, 275 (67.9%), agreed on having HIV
- 132 hospital services if the HCW was a familiar person from their neighborhood (Table 3).

134	Table 3. Self-discrimination and stigmatization
-----	---

	Frequency (%)
Having separated HIV clinic	355 (87.4)
Inclusive HIV clinic	26 (6.4)
Anyhow is better	18 (4.4)
None of the above	7 (1.7)
It is a free space for HIV patients	309 (87.0)
I am comfortable seeing others with HIV, knowing that I am not alone	99 (27.9)
I just like how the things are	35 (9.9)
So as to avoid the long waiting queue at the inclusive clinic	28 (7.9)
Yes	275 (67.9)
No	130 (32.1)
Because of the stigma that I will receive	56 (43.4)
Because of fear that HCW will disclose my health status	53 (41.1)
	Inclusive HIV clinic Anyhow is better None of the above It is a free space for HIV patients I am comfortable seeing others with HIV, knowing that I am not alone I just like how the things are So as to avoid the long waiting queue at the inclusive clinic Yes No

Because I do not prefer people who know me to know my health status	30 (23.3)
Inside its container	320 (78.8)
Anywhere but not inside its container	36 (8.9)
Inside my handbag	34 (8.4)
Inside plastic bag	30 (7.4)
Inside an envelope	15 (3.7)
Inside of the pockets of my clothes	10 (2.5)
I am not bothered by the sound; I do not do anything	227 (73.7)
I add a clean Handkerchief inside the container	31 (10.1)
I add leaflet paper inside the containers	27 (8.8)
I add clean cotton inside the container	18 (5.8)
I only take my medication when I am at home. I do not move with them	16 (5.2)
I do not move with medication inside the container. I keep them in the	10 (3.2)
hospital plastic bags	
On top of the cupboard	123 (30.3)
Inside clothes cupboard	118 (29.1)
	Inside its container Anywhere but not inside its container Inside my handbag Inside my handbag Inside plastic bag Inside an envelope Inside of the pockets of my clothes I am not bothered by the sound; I do not do anything I add a clean Handkerchief inside the container I add leaflet paper inside the containers I add clean cotton inside the containers I add clean cotton inside the container I only take my medication when I am at home. I do not move with them I do not move with medication inside the container. I keep them in the hospital plastic bags On top of the cupboard

	Under the bed	83 (20.4)
	Inside backpack	35 (8.6)
	In between clothes in the suitcase	29 (7.1)
	Inside dishes cupboard	19 (4.7)
	Inside the refrigerator	7 (1.7)
	Near the window	6 (1.5)
	Inside a drawer	5 (1.2)
	In the car	3 (0.7)
135		

138

139 Factors associated with viral load suppression

- 140 Analysis of factors associated with viral load suppression found that viruses were more suppressed
- 141 among female patients than their male counterparts (p = 0.036). Those on the dolutegravir-based
- 142 regimen also suppressed viral load more than those on other regimens (p = 0.050). Participants
- 143 with a refill interval of three months had more viral suppression than those with six months and
- 144 additional months of refill interval with a p-value < 0.000 (p = 0.004) (Table 4).

145

146 **Table 4. Factors associated with viral load suppression**

- 147
- 148
- 149

Variable	Category	Total	Viral load	High viral	Р
			suppressed n (%)	load n (%)	value
Gender	Female	282	224 (79.4)	58 (20.6)	0.036*
n = 385					
	Male	103	72 (69.9)	31 (30.1)	
Regimen	DBR	362	283 (78.2)	79 (21.8)	0.050*
(n = 383)					
	Another regimen	21	11 (52.4)	10 (47.6)	
Refill	Three months	212	176 (83.3)	36 (16.3)	0.000*
Interval					

(n - 207)	Size an arath a	00	05 (0()	4 (4 0)	
(n = 387)	Six months	99	95 (96)	4 (4.0)	
	One month	69	23 (33.3)	46 (66.7)	
	Two months	7	2 (28.6)	5 (71.4)	
HCW	They would continue	255	207 (81.2)	48 (18.8)	
(n = 384)	with service if the				0.004*
	HCW is a familiar				
	person from their				
	neighborhood				
	They would NOT	129	88 (68.2)	41(31.8)	
	continue with hospital				
	service if the HCW is a				
	familiar person from				
	their neighborhood				

Key: *Statistically significant by Chi-square,

HCWs: Health care workers, DBR: Dolutegravir-based regimen

150
151
152
153
154 Regression analysis of factors associated with viral load suppression
155 On a multivariate analysis, male patients were 60% less likely to have viral load suppression
156 compared to female patients (adjusted odds ratio [aOR]: 0.4, 95% confidence interval [95%]: 0.19

157 - 0.77, p = 0.007). Refill interval was significantly associated with viral load suppression. For

- example, patients with one-month refill intervals had odds of 0.01 (95%CI: 0.003-0.42, p < 0.0001)
- as compared to those with six months refill intervals (Table 5).

Variable	Category	aOR (95%CI)	P value
Gender	Male	0.4 (0.19 - 0.77)	0.007*
	Female	Reference	< 0.0001*
Refill interval	One month	0.01 (0.003 - 0.42)	< 0.0001*
	Two months	0.01 (0.00 - 0.088)	< 0.0001*
	Three months	0.2 (0.054 - 0.566)	0.004*
	Six months	Reference	
Adherence	Adherent	1.2 (0.552 - 2.408)	0.705
	Non-adherent	Reference	
Name of facility	Temeke RRH	1.5 (0.735 – 3.02)	0.269
	Amana RRH	Reference	
Regimen used	DBR	1.1 (0.125 – 9.384)	0.942
	Non-DBR	Reference	

160 Table 5. Multinomial logistics regression of factors associated with viral load suppression

*Statistically significant, aOR: Adjusted Odds Ratio, 95%CI: 95% confidence interval,

RRH: Regional referral hospital, DBR: Dolutegravir-based regimen

162 **Discussion**

163 The study was conducted one year after introducing the dolutegravir-based regimen as the 164 preferred default first line for managing HIV among adults in Tanzania [15], making the study the

165 first to report the proportion of people who have been switched to dolutegravir-based regimens.

166 This study found that most participants (87.4 %) preferred having a separate HIV clinic for HIV

167 patients. When asked for a reason, they responded that a separate clinic would ensure their privacy

168 by concealing their daily medication to the community surrounding PLHIV. It was further revealed

169 that PLHIV tends to change the containers of medication. Most PLHIV reported using plastic bags,

170 envelopes and handbags to carry their medication. This practice impairs the quality of ARV and,

in turn, may result in low viral load suppression. However, in our study, the variable did notsignificantly affect viral load suppression.

When asked where they store their medication at home, most study participants (30.3%) responded that they hide their medication in the cupboard. This was consistent with a study done in South Africa by Flynn and colleagues [17], which indicated that most participants reported using the refrigerator or a typical cupboard to store their medication [17].

In addition, our study revealed that 78.2% of the respondents on dolutegravir-based regimens achieved viral load suppression. This proportion is less compared to the study done in Uganda in 2018, where 94% of PLHIV on dolutegravir achieved viral load suppression [5]. Also, this finding was below national data on viral load suppression, where 87.0% of adults on ART in Tanzania were reported to have suppressed viral loads [15]. However, this finding may be limited to a period of one year after the introduction of the dolutegravir regimen in Tanzania.

The female gender was significantly associated with viral load suppression. This is inconsistent with other studies in Uganda in 2014-2015 on factors associated with viral load non-suppression [18]. This study's significant association between viral load suppression and refill time interval may be because the Tanzania National treatment guideline prescribes that PLHIV who consistently maintain viral load suppression are given a longer refill time interval [15].

188 Most of the study participants (67.9%) agreed on having HIV hospital services if the HCW is a 189 person they know from their neighborhood compared to the 32.1% of participants who did not 190 agree to be served by familiar healthcare personnel. Of all PLHIV not willing to be served by a 191 familiar HCW, 43.4% reported the fear of stigmatization, while 41.1% feared that HCW would 192 disclose their health status. Similar results were reported in the perpetuation of stigma by HCWs 193 may have a more significant impact on the continuum of care outcomes of PLWH in research [19]. 194 There was a significant association between viral load suppression and participants' HCW 195 preference for getting hospital service from the HCW familiar to them and coming from their 196 neighborhood. The participants who were not particular about the HCW who served them were 197 more likely to have viral suppression compared to those who would not continue with hospital 198 service if the HCW was a familiar person from their neighborhood [20].

Our results are based on the self-reported perception of stigma. Self-reported data is usually subject to potential recall bias and social desirability. To minimize this bias, some information, such as socio-demographic characteristics and viral load information, was obtained from hospital records. Also, patients were requested to skip questions they did not remember rather than guessing the responses.

204 Conclusion

Elements of self-perceived stigma appeared to influence the viral load suppression among PLHIV in Dar es Salaam, Tanzania. Factors such as gender and refill time interval were significantly associated with viral load suppression among HIV patients in the Dar es Salaam region. More counseling on stigmatization and its effects on PLHIV is needed to stop self-stigmatization.

209 Acknowledgments

We thank all the participants who agreed and consented to participate in this study. We also thank
health care providers at Centres for Treatment and Counselling for their dedicated cooperation
during the data collection phase.

214 **References**

- 215 1. Bvochora T, Satyanarayana S, Takarinda KC, Bara H, Chonzi P, Komtenza B, et al.
- 216 Enhanced adherence counselling and viral load suppression in HIV seropositive patients
- 217 with an initial high viral load in Harare, Zimbabwe: Operational issues. Mor O, editor.

218 PLoS One. 2019;14: e0211326. doi:10.1371/journal.pone.0211326

- 219 2. Omosanya OE, Elegbede OT, Agboola SM, Isinkaye AO, Omopariola OA. Effects of
- 220 Stigmatization/Discrimination on Antiretroviral Therapy Adherence among HIV-Infected
- 221 Patients in a Rural Tertiary Medical Center in Nigeria. J Int Assoc Provid AIDS Care.
- 222 2014;13: 260–263. doi:10.1177/2325957413475482
- 223 3. Bernays S, Paparini S, Seeley J, Rhodes T. "Not Taking it Will Just be Like a Sin": Young

- 224 People Living with HIV and the Stigmatization of Less-Than-Perfect Adherence to
- Antiretroviral Therapy. Med Anthropol. 2017;36: 485–499.
- doi:10.1080/01459740.2017.1306856
- 4. Tsai AC, Bangsberg DR, Kegeles SM, Katz IT, Haberer JE, Muzoora C, et al. Internalized
- 228 Stigma, Social Distance, and Disclosure of HIV Seropositivity in Rural Uganda. Ann
- 229 Behav Med. 2013;46: 285–294. doi:10.1007/s12160-013-9514-6
- 230 5. Nabitaka VM, Nawaggi P, Campbell J, Conroy J, Harwell J, Magambo K, et al. High
- acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in
- 232 pilot sites in Uganda: A mixed-methods prospective cohort study. Torpey K, editor. PLoS
- 233 One. 2020;15: e0232419. doi:10.1371/journal.pone.0232419
- 234 6. Dean Wantland W-TC. Engagement with Health Care Providers Affects Self-Efficacy,
- 235 Self-Esteem, Medication Adherence and Quality of Life in People Living with HIV. J

AIDS Clin Res. 2013;04: 1–14. doi:10.4172/2155-6113.1000256

- 237 7. United Republic of Tanzania. National Beaural of Statistics: 2012 Population and Housing
- 238 Census Population Distribution by Administrative areas. Natl Bur Stat Minist Financ.
- 239 2013; 177,180.
- Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical
 studies. Gastroenterol Hepatol from bed to bench. 2013;6: 14–7.
- 242 9. Sangeda RZ, Mosha F, Aboud S, Kamuhabwa A, Chalamilla G, Vercauteren J, et al.
- 243 Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment
- center in Tanzania. Drug Healthc Patient Saf. 2018;10: 79–88.
- 245 doi:10.2147/DHPS.S143178
- 246 10. Dehens J, de Hemptinne M, Galouchka M, Sajud A, van Otzel RP, Vanhoorebeeck C, et

- al. Exploring the value and acceptability of peer support in the process of improving
- adherence to HIV antiretroviral drugs in Tanzania, Dar-es-Salaam. Transdiscipl Insights.
- 249 2017;1: 9–32. doi:10.11116/TDI2017.1.2
- 250 11. Mosha F, Ledwaba J, Ndugulile F, Ng'ang'a Z, Nsubuga P, Morris L, et al. Clinical and
- 251 virological response to antiretroviral drugs among HIV patients on first-line treatment in
- 252 Dar-es-Salaam, Tanzania. J Infect Dev Ctries. 2014;8: 845–52. doi:10.3855/jidc.3879
- 253 12. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
- 254 consortium: Building an international community of software platform partners. J Biomed
- 255 Inform. 2019;95: 103208. doi:10.1016/j.jbi.2019.103208
- 256 13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
- 257 capture (REDCap)--a metadata-driven methodology and workflow process for providing
- translational research informatics support. J Biomed Inform. 2009;42: 377–81.
- doi:10.1016/j.jbi.2008.08.010
- 260 14. USAID. Understanding and Challenging HIV Stigma toward Entertainment Workers.
- 261 2007 [cited 19 Aug 2021] p. 143. Available: https://www.icrw.org/wp-
- 262 content/uploads/2016/10/Understanding-and-Challenging-HIV-Stigma-toward-
- 263 Entertainment-Workers-Toolkit-for-Action.pdf
- 15. United Republic of Tanzania. National Guidelines for the management of HIV and AIDS
 in Tanzania. 2019 [cited 30 May 2021]. Available:
- 266 http://www.nacp.go.tz/download/national-guidelines-for-the-management-of-hiv-and-
- 267 aids/
- 268 16. Kilipamwambu A, Bwire GM, Myemba DT, Njiro BJ, Majigo M V. WHO/INRUD core
- 269 prescribing indicators and antibiotic utilization patterns among primary health care

270 facilities in Ilala distric	, Tanzania. JA	C-Antimicrobial Res	sist. 2021;3: 1–7
---------------------------------	----------------	---------------------	-------------------

- 271 doi:10.1093/jacamr/dlab049
- 272 17. Flynn AD, Scheuerle RL, Galgon G, Gerrard SE, Netshandama VO. An assessment of
- 273 infant medication administration and storage practices in selected communities in the
- 274 Vhembe District of Limpopo Province, South Africa. Heal SA Gesondheid. 2019;24: 1–7.
- doi:10.4102/hsag.v24i0.1075
- 276 18. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors
- 277 Associated with Virological Non-suppression among HIV-Positive Patients on
- Antiretroviral Therapy in Uganda, August 2014–July 2015. BMC Infect Dis. 2017;17:
- 279 326. doi:10.1186/s12879-017-2428-3
- 280 19. Algarin AB, Sheehan DM, Varas-Diaz N, Fennie KP, Zhou Z, Spencer EC, et al. Health
- 281 Care-Specific Enacted HIV-Related Stigma's Association with Antiretroviral Therapy
- Adherence and Viral Suppression Among People Living with HIV in Florida. AIDS

283 Patient Care STDS. 2020;34: 316–326. doi:10.1089/apc.2020.0031

- 284 20. Kiekens A, Dehens J, de Hemptinne M, Galouchka M, Vanhoorebeeck C, van Otzel RP,
- 285 et al. HIV-related Peer Support in Dar es Salaam: A Pilot Questionnaire Inquiry.
- 286 Transdiscipl Insights. 2019;3: 1–18. doi:10.11116/TDI2019.3.1